Basis of Muscle Dysfunction in Malignant Hyperthermia and Central Core Disease
恶性高热和中央核心疾病中肌肉功能障碍的基础
基本信息
- 批准号:8608998
- 负责人:
- 金额:$ 65.84万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2006
- 资助国家:美国
- 起止时间:2006-04-01 至 2016-01-31
- 项目状态:已结题
- 来源:
- 关键词:AMP-activated protein kinase kinaseAcetylcysteineAgingAminoimidazole CarboxamideAnestheticsAntioxidantsAutomobile DrivingBindingCalciumCentral Core MyopathyCessation of lifeContractureCoupledCouplingDantroleneDevelopmentDietDihydropyridine ReceptorsDiseaseDominant-Negative MutationExerciseExhibitsFDA approvedFatty acid glycerol estersFunctional disorderGenesGoalsHeatingHumanInterventionLifeLigandsLinkMalignant hyperpyrexia due to anesthesiaMetabolismMitochondriaModelingMusMuscleMuscle functionMutationMyopathyOutcomeOxidative StressParalysedPathway interactionsProcessProductionProteinsResearchResearch PersonnelRhabdomyolysisRibonucleotidesRoleRyR1Ryanodine Receptor Calcium Release ChannelSarcoplasmic ReticulumSkeletal MuscleSymptomsTacrolimus Binding Protein 1ATacrolimus Binding ProteinsTechnologyTemperatureTestingTherapeutic InterventionWorkbasecongenital myopathyefficacy testingflexibilityimprovedin vivoinnovationmouse modelnovel therapeutic interventionpreventpublic health relevanceresponsetherapy designtreatment strategyvoltage
项目摘要
DESCRIPTION (provided by applicant): Mutations in the RYR1 gene underlie several debilitating, life-threatening muscle diseases. In this application we are proposing to use a mouse model with a knockin mutation into RyR1 (Y524S) that has features of three of these disorders: malignant hyperthermia (MH) heat/exercise-induced exertional rhabdomyolysis (ER) and central core disease (CCD). Our long term goals are to define the mechanisms that underlie the decline in muscle function associated with these diseases and to develop new interventions. Our overall working hypothesis for the current proposal the Y524S mutation in RyR1 increases the temperature sensitivity of both excitation-contraction coupling (ECC) and RyR1 Ca2+ leak, producing the MH response and driving oxidative stress and mitochondrial destruction that leads to the myopathy. Our specific aims are to: 1) Elucidate the role of Ca2+ influx via CaV1.1 in the MH response and the development of the myopathy; 2) Delineate the mechanisms of core formation in YS mice; 3) Define the mechanism by which an activator (AICAR) of the energy sensing kinase AMPK prevents the MH response and evaluate AICAR's ability to slow the development of the myopathy in YS mice; and 4) Define the mechanism by which a non-immunosuppressive ligand for the protein FKBP12 prevents the MH response and evaluate SLF's effect on the myopathy in YS mice. The proposed work is highly significant because we directly couple the delineation of pathways underlying disease processes with the development of novel therapeutic interventions that have distinct mechanisms of action, allowing for some flexibility to tailor treatment strategies to different mutations associated with MH and CCD. The proposed research is innovative because of: 1) paradigm shifting hypotheses; 2) unique mouse models, 3) cutting edge technologies, and 4) therapeutic interventions never previously proposed as treatments for MH or other RyR1-linked myopathies.
描述(申请人提供):RYR1基因突变是几种衰弱的、危及生命的肌肉疾病的基础。在这项应用中,我们建议使用RyR1(Y524S)敲击突变的小鼠模型,该模型具有以下三种疾病的特征:恶性高热(MH)、热/运动诱导的劳力性横纹肌溶解(ER)和中枢性核心病(CCD)。我们的长期目标是确定与这些疾病相关的肌肉功能下降的基础机制,并开发新的干预措施。我们对当前建议的总体工作假设是,RyR1的Y524S突变增加了兴奋收缩偶联(ECC)和RyR1钙泄漏的温度敏感性,产生MH反应,并驱动氧化应激和线粒体破坏,从而导致肌病。我们的具体目标是:1)阐明通过CaV1.1进行的钙离子内流在MH反应和肌病发展中的作用;2)描述YS小鼠核心形成的机制;3)确定能量感应激酶AMPK的激活剂(AICAR)阻止MH反应的机制并评估AICAR减缓YS小鼠肌病发展的能力;以及4)确定非免疫抑制配体FKBP12阻止MH反应的机制,并评价SLF对YS小鼠肌病的影响。拟议的工作具有非常重要的意义,因为我们直接将疾病过程潜在途径的描绘与具有不同作用机制的新型治疗干预措施的开发结合在一起,允许有一定的灵活性来针对与MH和CD相关的不同突变定制治疗策略。这项拟议的研究具有创新性,因为:1)范式转换假说;2)独特的小鼠模型;3)尖端技术;4)以前从未被提出用于治疗MH或其他RyR1相关肌病的治疗干预措施。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Robert T Dirksen其他文献
Robert T Dirksen的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Robert T Dirksen', 18)}}的其他基金
RYR-1-Related Diseases International Research Workshop: From Mechanisms to Treatments
RYR-1相关疾病国际研究研讨会:从机制到治疗
- 批准号:
10531507 - 财政年份:2022
- 资助金额:
$ 65.84万 - 项目类别:
Characterization of the Exercise-induced Orai1 Proteome in Skeletal Muscle
运动诱导的骨骼肌 Orai1 蛋白质组的表征
- 批准号:
10604393 - 财政年份:2022
- 资助金额:
$ 65.84万 - 项目类别:
Characterization of the Exercise-induced Orai1 Proteome in Skeletal Muscle
运动诱导的骨骼肌 Orai1 蛋白质组的表征
- 批准号:
10463233 - 财政年份:2022
- 资助金额:
$ 65.84万 - 项目类别:
Redefining the Role of FKBP12 in Skeletal Muscle
重新定义 FKBP12 在骨骼肌中的作用
- 批准号:
10359698 - 财政年份:2018
- 资助金额:
$ 65.84万 - 项目类别:
Redefining the Role of FKBP12 in Skeletal Muscle
重新定义 FKBP12 在骨骼肌中的作用
- 批准号:
10116962 - 财政年份:2018
- 资助金额:
$ 65.84万 - 项目类别:
Orai1 as a Therapeutic Target for Muscular Dystrophy
Orai1 作为肌营养不良症的治疗靶点
- 批准号:
9283626 - 财政年份:2016
- 资助金额:
$ 65.84万 - 项目类别:
2015 Muscle: Excitation/Contraction Coupling Gordon Research Conference & Gordon Research Seminar
2015年肌肉:兴奋/收缩耦合戈登研究会议
- 批准号:
8825143 - 财政年份:2014
- 资助金额:
$ 65.84万 - 项目类别:
Molecular Mechanism and Functional Role of SOCE in Skeletal Muscle
SOCE在骨骼肌中的分子机制和功能作用
- 批准号:
8477131 - 财政年份:2010
- 资助金额:
$ 65.84万 - 项目类别:
Molecular Mechanism and Functional Role of SOCE in Skeletal Muscle
SOCE在骨骼肌中的分子机制和功能作用
- 批准号:
9102666 - 财政年份:2010
- 资助金额:
$ 65.84万 - 项目类别:
Molecular Mechanism and Functional Role of SOCE in Skeletal Muscle
SOCE在骨骼肌中的分子机制和功能作用
- 批准号:
9248866 - 财政年份:2010
- 资助金额:
$ 65.84万 - 项目类别:
相似海外基金
抗酸化能を高めたN-acetylcysteineによる老視と白内障抑制機構の解明
阐明具有增强抗氧化能力的N-乙酰半胱氨酸抑制老花眼和白内障的机制
- 批准号:
23K15945 - 财政年份:2023
- 资助金额:
$ 65.84万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Targeting the neurobiology of restricted and repetitive behaviors in children with autism using N-acetylcysteine
使用 N-乙酰半胱氨酸针对自闭症儿童限制性和重复性行为的神经生物学
- 批准号:
10758985 - 财政年份:2023
- 资助金额:
$ 65.84万 - 项目类别:
Targeting the neurobiology of restricted and repetitive behaviors in children with autism using N-acetylcysteine
使用 N-乙酰半胱氨酸针对自闭症儿童限制性和重复性行为的神经生物学
- 批准号:
10619173 - 财政年份:2022
- 资助金额:
$ 65.84万 - 项目类别:
High dose acetaminophen with n-acetylcysteine rescue as a novel STAT3 inhibitor with anti-cancer stem cell properties
高剂量对乙酰氨基酚与 n-乙酰半胱氨酸救援作为具有抗癌干细胞特性的新型 STAT3 抑制剂
- 批准号:
10517287 - 财政年份:2021
- 资助金额:
$ 65.84万 - 项目类别:
A randomised controlled trial of N-acetylcysteine for the treatment of alcohol use disorder
N-乙酰半胱氨酸治疗酒精使用障碍的随机对照试验
- 批准号:
nhmrc : 2001375 - 财政年份:2021
- 资助金额:
$ 65.84万 - 项目类别:
Clinical Trials and Cohort Studies Grants
High dose acetaminophen with n-acetylcysteine rescue as a novel STAT3 inhibitor with anti-cancer stem cell properties
高剂量对乙酰氨基酚与 n-乙酰半胱氨酸救援作为具有抗癌干细胞特性的新型 STAT3 抑制剂
- 批准号:
10368472 - 财政年份:2021
- 资助金额:
$ 65.84万 - 项目类别:
Targeting the neurobiology of restricted and repetitive behaviors in children with autism using N-acetylcysteine
使用 N-乙酰半胱氨酸针对自闭症儿童限制性和重复性行为的神经生物学
- 批准号:
10221760 - 财政年份:2020
- 资助金额:
$ 65.84万 - 项目类别:
N-acetylcysteineの骨治癒促進効果の検討
N-乙酰半胱氨酸促进骨愈合作用的考察
- 批准号:
20H01118 - 财政年份:2020
- 资助金额:
$ 65.84万 - 项目类别:
Grant-in-Aid for Encouragement of Scientists














{{item.name}}会员




